TY - JOUR
T1 - Phase I Immunotoxin Trial in Patients with B-Cell Lymphoma
AU - Vitetta, Ellen S.
AU - Stone, Marvin
AU - Amlot, Peter
AU - Fay, Joseph
AU - May, Richard
AU - Till, Mark
AU - Newman, Joe
AU - Clark, Patty
AU - Collins, Robert
AU - Cunningham, D.
AU - Ghetie, Victor
AU - Uhr, Jonathan W.
AU - Thorpe, Philip E.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1991/8
Y1 - 1991/8
N2 - Fifteen patients with refractory B-cell lymphoma were treated in a Phase I dose escalation clinical trial with a highly potent immunotoxin consisting of the Fab’ fragment of a monoclonal anti-CD22 antibody (RFB4) coupled to chemically deglycosylated ricin A chain. All patients had low, intermediate, or high grade non-Hodgkin's lymphoma. The immunotoxin was administered i.v. in two to six doses at 48-h intervals. The peak serum concentration and the t,-_ were not dose dependent among patients and averaged 1.3 Mg/ml and 86 min, respectively. Three patients made antibody against A chain, and a fourth made antibody against both A chain and mouse immunoglobulin. Antibody responses were low (<85 /g/ml)in three patients and were not detected until 1 mo after treatment. The maximum tolerated dose of the immunotoxin was 75 mg/m2. Dose-related toxicities included vascular leak syndrome, fever, anorexia, and myalgia. Dose-limiting toxicities included pulmonary edema and/or effusion, expressive aphasia, and rhabdomyolysis (resulting in reversible kidney failure). There was no evidence of liver dysfunction. Partial responses were achieved in 38% of evaluable patients, and in those patients who had >50% CD22* tumor cells, 50% of the patients achieved a partial response. Clinical responses were not related to tumor grade and were generally transient, lasting between 1 and 4 mo.
AB - Fifteen patients with refractory B-cell lymphoma were treated in a Phase I dose escalation clinical trial with a highly potent immunotoxin consisting of the Fab’ fragment of a monoclonal anti-CD22 antibody (RFB4) coupled to chemically deglycosylated ricin A chain. All patients had low, intermediate, or high grade non-Hodgkin's lymphoma. The immunotoxin was administered i.v. in two to six doses at 48-h intervals. The peak serum concentration and the t,-_ were not dose dependent among patients and averaged 1.3 Mg/ml and 86 min, respectively. Three patients made antibody against A chain, and a fourth made antibody against both A chain and mouse immunoglobulin. Antibody responses were low (<85 /g/ml)in three patients and were not detected until 1 mo after treatment. The maximum tolerated dose of the immunotoxin was 75 mg/m2. Dose-related toxicities included vascular leak syndrome, fever, anorexia, and myalgia. Dose-limiting toxicities included pulmonary edema and/or effusion, expressive aphasia, and rhabdomyolysis (resulting in reversible kidney failure). There was no evidence of liver dysfunction. Partial responses were achieved in 38% of evaluable patients, and in those patients who had >50% CD22* tumor cells, 50% of the patients achieved a partial response. Clinical responses were not related to tumor grade and were generally transient, lasting between 1 and 4 mo.
UR - http://www.scopus.com/inward/record.url?scp=0026375173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026375173&partnerID=8YFLogxK
M3 - Article
C2 - 1855219
AN - SCOPUS:0026375173
VL - 51
SP - 4052
EP - 4058
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 15
ER -